The CBR3-AS1/miR-25-3p/JNK1/MEK4 axis provides insight into breast cancer drug resistance mechanisms and theoretical support in the search for new breast cancer diagnostic markers and specific therapeutic targets. This evidence concerns the gene MAP2K4 and breast cancer.